[go: up one dir, main page]

WO2014166500A3 - Peptides having immune suppresive domains for transfection - Google Patents

Peptides having immune suppresive domains for transfection Download PDF

Info

Publication number
WO2014166500A3
WO2014166500A3 PCT/DK2014/050089 DK2014050089W WO2014166500A3 WO 2014166500 A3 WO2014166500 A3 WO 2014166500A3 DK 2014050089 W DK2014050089 W DK 2014050089W WO 2014166500 A3 WO2014166500 A3 WO 2014166500A3
Authority
WO
WIPO (PCT)
Prior art keywords
transfection
immune
suppresive
domains
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2014/050089
Other languages
French (fr)
Other versions
WO2014166500A2 (en
Inventor
Shervin Bahrami
Christian KANSTRUP HOLM
Søren RIIS PALUDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SKAU APS
Aarhus Universitet
Original Assignee
SKAU APS
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SKAU APS, Aarhus Universitet filed Critical SKAU APS
Priority to EP14722536.1A priority Critical patent/EP2984171A2/en
Publication of WO2014166500A2 publication Critical patent/WO2014166500A2/en
Publication of WO2014166500A3 publication Critical patent/WO2014166500A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a use of a peptide, comprising an immune suppressive domain, for transfection. In particular, the present invention relates to the use of the peptide for immune suppression in a transfection mix, wherein the peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
PCT/DK2014/050089 2013-04-10 2014-04-10 Peptides having immune suppresive domains for transfection Ceased WO2014166500A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14722536.1A EP2984171A2 (en) 2013-04-10 2014-04-10 Peptides having immune suppresive domains for transfection

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
DKPA201370201 2013-04-10
DKPA201370200 2013-04-10
DKPA201370202 2013-04-10
DKPA201370201 2013-04-10
DKPA201370200 2013-04-10
DKPA201370202 2013-04-10
DKPA201370204 2013-04-11
DKPA201370204 2013-04-11
DKPA201370203 2013-04-11
DKPA201370203 2013-04-11

Publications (2)

Publication Number Publication Date
WO2014166500A2 WO2014166500A2 (en) 2014-10-16
WO2014166500A3 true WO2014166500A3 (en) 2014-12-24

Family

ID=50685717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2014/050089 Ceased WO2014166500A2 (en) 2013-04-10 2014-04-10 Peptides having immune suppresive domains for transfection

Country Status (2)

Country Link
EP (1) EP2984171A2 (en)
WO (1) WO2014166500A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
MX2022005498A (en) * 2019-11-07 2022-08-11 Inst Microbiology Cas ZIKA/DENGUE VACCINE AND APPLICATION OF THE SAME.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040502A1 (en) * 1997-03-14 1998-09-17 Life Technologies, Inc. Peptide-enhanced transfections
WO2005026337A2 (en) * 2003-09-18 2005-03-24 Institut Gustave Roussy Adenoviral vector for infecting cells deficient in a car receptor
WO2009065618A2 (en) * 2007-11-22 2009-05-28 Biontex Laboratories Gmbh Improvement of transfection results of non-viral gene delivery systems by influencing the congenital immune system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932274A (en) 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040502A1 (en) * 1997-03-14 1998-09-17 Life Technologies, Inc. Peptide-enhanced transfections
WO2005026337A2 (en) * 2003-09-18 2005-03-24 Institut Gustave Roussy Adenoviral vector for infecting cells deficient in a car receptor
WO2009065618A2 (en) * 2007-11-22 2009-05-28 Biontex Laboratories Gmbh Improvement of transfection results of non-viral gene delivery systems by influencing the congenital immune system

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRANDON K SACK ET AL: "Evading the immune response upon in vivo gene therapy with viral vectors", CURRENT OPINION IN MOLECULAR THERAPEUTICS, 1 October 2009 (2009-10-01), England, pages 493 - 503, XP055128231, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/19806497> *
HARAGUCHI S ET AL: "A potent immunosuppressive retroviral peptide: cytokine patterns and signaling pathways", IMMUNOLOGIC RESEARCH, HUMANA PRESS, INC, US, vol. 41, no. 1, 1 May 2008 (2008-05-01), pages 46 - 55, XP002591496, ISSN: 0257-277X, [retrieved on 20070515], DOI: 10.1007/S12026-007-0039-6 *
KARRA DANIELA ET AL: "Transfection Techniques for Neuronal Cells", JOURNAL OF NEUROSCIENCE, vol. 30, no. 18, May 2010 (2010-05-01), pages 6171 - 6177, XP002727325, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.0183-10.2010 *
KLUCZYK ALICJA ET AL: "Dimeric analogs of immunosuppressive decapeptide fragment of ubiquitin", JOURNAL OF PEPTIDE SCIENCE, vol. 18, no. 7, July 2012 (2012-07-01), pages 456 - 465, XP002727324, DOI: 10.1002/PSC.2416 *
SAKURAI ET AL: "Innate immune response induced by gene delivery vectors", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 354, no. 1-2, 20 March 2008 (2008-03-20), pages 9 - 15, XP022550484, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2007.06.012 *
XIUCUI MA ET AL: "Improvements in Mucopolysaccharidosis I Mice After Adult Retroviral Vector-mediated Gene Therapy with Immunomodulation", MOLECULAR THERAPY, vol. 15, no. 5, 1 May 2007 (2007-05-01), pages 889 - 902, XP055128247, ISSN: 1525-0016, DOI: 10.1038/sj.mt.6300112 *

Also Published As

Publication number Publication date
EP2984171A2 (en) 2016-02-17
WO2014166500A2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
IL285273B (en) A new complex containing a cell-penetrating protein, a cargo and an agonist of the tlr protein
EP3200812B8 (en) Novel alpha4beta7 peptide monomer and dimer antagonists
MX2019003214A (en) Stable dual variable domain immunoglobulin protein formulations.
MX374811B (en) ANTI-TAU ANTIBODIES AND METHODS OF USE.
MX2019011952A (en) Anti-garp protein and uses thereof.
IL243209B (en) Cyclic peptides as protein targeting agents
EP2961778A4 (en) COMPOSITION COMPRISING TWO CATALYSTS OF OLEFIN METATHESIS OF CARBENE METALLIC TYPE
PH12016502282B1 (en) Improved immunoglobulin variable domains
EP2970490A4 (en) Antibodies to mica and micb proteins
EP3236772A4 (en) Methods of purifying recombinant proteins
EP3341395A4 (en) Improved cell-permeable (icp)-socs3 recombinant protein and uses thereof
EP3544623A4 (en) Cell-penetrating peptide sequences
EP3201217A4 (en) Novel cyclic monomer and dimer peptides having integrin antagonist activity
UA106900C2 (en) LibreOfficeDR5-BINDING POLYPEPTIDE
EP3166959A4 (en) Targeting peptides that bind s. mutans, constructs comprising such peptides and uses thereof
EP3529280A4 (en) Antibodies to mica and micb proteins
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
EP3020724A4 (en) Cell-penetrating peptide and conjugate comprising same
EP3309169A4 (en) Antibody binding specifically to isolated vimentin-derived peptide, or binding fragment of the peptide
NZ731491A (en) Cd83 binding proteins and uses thereof
EP2986115A4 (en) Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain
EP3024844A4 (en) Short peptides derived from vdac1, compositions and methods of use thereof
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
WO2014166500A3 (en) Peptides having immune suppresive domains for transfection
WO2014152831A3 (en) Targeting peptides and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14722536

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2014722536

Country of ref document: EP